Cited by 239Alzheimer's disease research and treatmentsAutophagy in Disease and TherapyMitochondrial Function and Pathology

Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession

Open access
Liu, Dong, Pitta, Michael, Jiang, Haiyang, Lee, Jong-Hwan, Zhang, Guofeng, Chen, Xinzhi, Kawamoto, Elisa M., Mattson, Mark P.·2013·Neurobiology of Aging

Abstract

Impaired brain energy metabolism and oxidative stress are implicated in cognitive decline and the pathologic accumulations of amyloid β-peptide (Aβ) and hyperphosphorylated tau in Alzheimer's disease (AD). To determine whether improving brain energy metabolism will forestall disease progress in AD, the impact of the β-nicotinamide adenine dinucleotide precursor nicotinamide on brain cell mitochondrial function and macroautophagy, bioenergetics-related signaling, and cognitive performance were studied in cultured neurons and in a mouse model of AD. Oxidative stress resulted in decreased mitochondrial mass, mitochondrial degeneration, and autophagosome accumulation in neurons. Nicotinamide preserved mitochondrial integrity and autophagy function, and reduced neuronal vulnerability to oxidative/metabolic insults and Aβ toxicity. β-Nicotinamide adenine dinucleotide biosynthesis, autophagy, and phosphatidylinositol-3-kinase signaling were required for the neuroprotective action of nicotinamide. Treatment of 3xTgAD mice with nicotinamide for 8 months resulted in improved cognitive performance, and reduced Aβ and hyperphosphorylated tau pathologies in hippocampus and cerebral cortex. Nicotinamide treatment preserved mitochondrial integrity, and improved autophagy-lysosome procession by enhancing lysosome/autolysosome acidification to reduce autophagosome accumulation. Treatment of 3xTgAD mice with nicotinamide resulted in elevated levels of activated neuroplasticity-related kinases (protein kinase B [Akt] and extracellular signal-regulated kinases) and the transcription factor cyclic adenosine monophosphate (AMP) response element-binding protein in the hippocampus and cerebral cortex. Thus, nicotinamide suppresses AD pathology and cognitive decline in a mouse model of AD by a mechanism involving improved brain bioenergetics with preserved functionality of mitochondria and the autophagy system.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2012.11.020

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In neurodegenerative mouse models including AD, HD, and premature aging A-T, NAD+ augmentation increases BDNF expression and activity, leading to enhanced synaptic plasticity and function.

    “In different neurodegenerative mouse models including AD, HD, and the premature aging disease A-T, NAD+ augmentation increases the expression and activity of BDNF, leading to enhanced synaptic plasticity and function (Fang et al., 2016a; Hathorn et al., 2011; Liu et al., 2013).”

    From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Liu et al., 2013

  • Exposure of cultured rat cortical neurons to aggregating Aβ results in reduced NAD+ levels.

    “Exposure of cultured rat cortical neurons to aggregating Aβ results in reduced NAD+ levels (Liu et al., 2013).”

    From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Liu et al., 2013

  • NAD+ augmentation inhibited Alzheimer's disease-related pathology and cognitive decline in different AD animal models, including 3xTgAD mice treated with nicotinamide, 3xTgAD/Polβ+/− mice treated with nicotinamide riboside, and neuronal Aβ1-42 and Tau transgenic C. elegans models.

    “Accordingly, NAD+ augmentation inhibited AD-related pathology and cognitive decline in different AD animal models, including 3xTgAD mice treated with NAM (Liu et al., 2013), 3xTgAD/Polβ+/− mice treated with NR (Hou et al., 2018), and in neuronal Aβ1–42 and the neuronal Tau (pro-aggregant F3ΔK280 tau fragment) transgenic C. elegans models (Fang et al., 2019) (summarized in Table 1).”

    From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Liu et al., 2013

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Liu, D., Pitta, M., Jiang, H., Lee, J.-H., Zhang, G., Chen, X., Kawamoto, E. M., & Mattson, M. P.
Affiliations
  • National Institute on Aging (US)
  • Konkuk University (KR)
  • National Institutes of Health (US)
Corresponding author
Mattson, Mark P.
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2013-06
Volume
34
Issue
6
Pages
1564-1580
ISSN
0197-4580 (ISSN-L)
OpenAlex
W1996656477
Cited by
238
References
101
Citations by year
2026: 11 · 2025: 29 · 2024: 23 · 2023: 19 · 2022: 21 · 2021: 37 · 2020: 16 · 2019: 17 · 2018: 17 · 2017: 13 · 2016: 10 · 2015: 10 · 2014: 8 · 2013: 7
FWCI
5.36
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Aging (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
Intramural Research Program of the National Institute on Aging
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords
nicotinamide, Alzheimer's disease, brain energy metabolism, mitochondrial function, autophagy, oxidative stress, amyloid-beta, hyperphosphorylated tau, 3xTg-AD mice, cognitive decline, phosphatidylinositol 3-kinase signaling, AMPK, lysosomal acidification, neuroprotection, hippocampus
MeSH terms
Alzheimer Disease, Animals, Autophagy, Cells, Cultured, Cognition Disorders, Disease Models, Animal, Energy Metabolism, Mice, Inbred C57BL, Mice, Transgenic, Neurons, Niacinamide, Vitamin B Complex, Oxidative Stress, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review